$ONCY

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer Study launched earlier this year is expected to confirm previous efficacy signal in 2L KRAS-mutant MSS colorectal cancer study that saw 17 months PFS

Oncolytics Biotech Inc. (ONCY) reported that FDA interactions suggest a potential expansion of its REO 033 study, which could support accelerated approval based on ORR and full approval on PFS. The study aims to validate prior efficacy signals from REO 022.

Oncolytics Biotech (Nasdaq: ONCY) presented a trial-in-progress abstract at ESMO Congress 2026 for its REO 033 study, evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line RAS-mutant MSS mCRC. The study aims to validate earlier efficacy signals from the REO 022 study, which showed improved outcomes compared to historical standards. The company plans to expand the trial to support potential accelerated approval.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 Final Cohort 4 results expected

Oncolytics Biotech Inc. expects final GOBLET Cohort 4 results in Q4 2026 and initial Cohort 5 results in H1 2027. The company also anticipates the final PanCAN grant payment this quarter, according to a press release.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term Three pa

Oncolytics Biotech Inc. announced new patents for its drug pelareorep in several countries, with U.S. issuance expected. The company plans additional IP protection for a modified version of the drug. According to Oncolytics, this move aims to extend exclusivity beyond existing manufacturing patents.

ONCOLYTICS BIOTECH INC (ONCY) filed an SEC Form 8-K — Other Events. Oncolytics Biotech ® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a phenotype

Oncolytics Biotech (Nasdaq: ONCY) announced data published in the Proceedings of the National Academy of Sciences showing pelareorep can alter the tumor microenvironment in liver cancer, making it susceptible to immunotherapy. The study demonstrated increased PD-L1 expression, ICOSL levels, and CD8+ T cell density. Oncolytics is developing pelareorep for metastatic gastrointestinal cancers and is pursuing strategic partnerships.